Get the Stockscreener App
0.6787
1.11%
-0.0012
Curanex Pharmaceuticals Inc stock is traded at $0.6787, with a volume of 49,892.
It is down -1.11% in the last 24 hours and down -14.10% over the past month.
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.
See More
Previous Close:
$0.6775
Open:
$0.666
24h Volume:
49,892
Relative Volume:
0.03
Market Cap:
$18.59M
Revenue:
-
Net Income/Loss:
$-435.00K
P/E Ratio:
-43.23
EPS:
-0.0157
Net Cash Flow:
$-665.30K
1W Performance:
-16.24%
1M Performance:
-14.10%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.6504
$0.6899
1-Week Range:
$0.6275
$0.83
52-Week Range:
$0.561
$9.1796
Curanex Pharmaceuticals Inc Stock (CURX) Company Profile
Name
Curanex Pharmaceuticals Inc
Sector
Industry
Phone
718-673-6078
Address
2 JERICHO PLAZA,, JERICHO
Compare CURX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CURX
Curanex Pharmaceuticals Inc
|
0.67 | 19.20M | 0 | -435.00K | -665.30K | -0.0157 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.69 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.02 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.18 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
825.84 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.89 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Curanex Pharmaceuticals Inc Stock (CURX) Latest News
Curanex Pharmaceuticals Inc (CURX) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
Curanex Pharmaceuticals IncCommon Stock (NQ: CURX - FinancialContent
Curanex Pharmaceuticals (CURX): An Emerging Force in US Botanical Drug Development - FinancialContent
Curanex Pharmaceuticals (CURX): An Emerging Force In US Botanical Drug Development - Menafn.com
Curanex engages Strategic Investor Relations to enhance Curanex’s visibility - TipRanks
Curanex Pharmaceuticals Inc. Engages Strategic Investor Relations to Enhance Investor Communications and Engagement - The Manila Times
Curanex Pharmaceuticals Inc. Engages Strategic Investor - GlobeNewswire
Price performance - Yahoo
Curanex Pharmaceuticals Inc trading resumes - MSN
Curanex Pharmaceuticals Issues Shares Post-IPO - TipRanks
Curanex Pharmaceuticals issues shares in private placement and repays insider loans - Investing.com
Curanex Pharmaceuticals Inc’s Quiet Period To End on October 6th (NASDAQ:CURX) - Defense World
Curanex Pharmaceuticals Inc (CURX) company profile and facts - Yahoo! Finance UK
Day 5 of Loss Streak for Curanex Pharmaceuticals Stock with -89% Return (vs. 64% YTD) [9/23/2025] - Trefis
Jun Liu Net Worth (2025) - GuruFocus
RXRX Stock Surges: What’s Next? - StocksToTrade
CURX Pharmaceuticals: A New Dawn or a Passing Surge? - StocksToTrade
Why Bullish Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Curanex Pharmaceuticals Inc trading halted, volatility trading pause - MSN
United States shares mixed at close of trade; Dow Jones Industrial Average up 0.57% - Investing.com India
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.57% - Investing.com
Technical Analysis of Curanex Pharmaceuticals Inc (NASDAQ:CURX) - TradingView
Finance Watch: LB Pharmaceuticals Launches Second-Largest Biopharma IPO Of 2025 In The US - Citeline News & Insights
Chinese Stocks To Follow Now – September 11th - Defense World
Curanex Pharmaceuticals announces pricing of its initial public offering - MSN
Curanex Pharmaceuticals Boosts IPO Proceeds with Share Sale - TipRanks
Curanex Pharmaceuticals Inc. Announces Exercise of the Over-Allotment Option by Underwriters - GlobeNewswire
$17.25M IPO Complete: Biotech Curanex Pharmaceuticals Secures Full Over-Allotment Exercise at $4/Share - Stock Titan
Curanex Pharmaceuticals Inc (CURX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Biopharma IPO activity slows, but 2025 returns are surging - BioWorld MedTech
Number of employees of Curanex Pharmaceuticals Inc – BOATS:CURX - TradingView
Curanex Pharmaceuticals Inc Financial Statements – NASDAQ:CURX - TradingView
Finance Watch: Ever The Outlier, Biotech Outpaces Broader Stocks - insights.citeline.com
Curanex Pharmaceuticals Inc Stock (CURX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.03%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):